All In Biotech

Drug Trial Radar · NCT06005597

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed Dose Combination Daily on Top of Maximally Tolerated Lipid-Modifying Therapy in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) and/or Atherosclerotic Cardiovascular Disease (ASCVD) or Multiple ASCVD Risk Factors

Last checked: Nov 19, 2026Latest source record: Oct 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 407 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

407

Actual

Start

Mar 1, 2024

Primary completion

Sep 25, 2024

Study completion Oct 16, 2024

Sponsor

Lead sponsor
NewAmsterdam PharmaIndustry
Sponsor type
Industry
First posted
Aug 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors to evaluate the efficacy, safety and tolerability of obicetrapib 10mg and ezetimibe 10mg fixed dose combination as an adjunct to diet and maximally tolerated lipid-lowering therapy.

Conditions

  • Dyslipidemias
  • Hypercholesterolemia
  • Familial Hypercholesterolemia
  • ASCVD
  • High Cholesterol

Interventions

  • Combination TherapyCombination product

    tablet; 10mg obicetrapib and 10mg ezetimibe fixed does combination

  • Monotherapy obicetrapibDrug

    tablet; 10mg obicetrapib

  • Monotherapy ezetimibeDrug

    capsule; 10mg ezetimibe

  • Combination Therapy placeboOther

    tablet; no active ingredient

  • Obicetrapib PlaceboOther

    tablet; no active ingredient

  • Ezetimibe PlaceboOther

    capsule; no active ingredient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-CTime frame: 84 Days
  2. Effect of Fixed Dose Combination (FDC) Compared to Ezetimibe Monotherapy on LDL-CTime frame: 84 Days
  3. Effect of Fixed Dose Combination (FDC) Compared to Obicetrapib Monotherapy on LDL-CTime frame: 84 Days
  4. Effect of Obicetrapib Monotherapy Compared to Placebo on LDL-CTime frame: 84 Days

Locations

45 sites in 1 country. Site status is shown where the registry gives one.

  • East Valley Diabetes & Endocrinology

    Gilbert, Arizona

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • Centricity Research - Columbus

    Columbus, Georgia

  • Center for Advanced Research and Education

    Gainesville, Georgia

  • NSC Research

    Johns Creek, Georgia

  • North Georgia Clinical Research

    Woodstock, Georgia

  • Evanston Premier Healthcare Research LLC

    Skokie, Illinois

  • Cardiovascular Research of Northwest Indiana, LLC

    Munster, Indiana

  • Grace Research, LLC - Bossier City, LA

    Bossier City, Louisiana

  • Horizon Research Group of Opelousas

    Eunice, Louisiana

  • Maryland Cardiovascular Specialists

    Baltimore, Maryland

  • TidalHealth Peninsula Regional, Inc.

    Salisbury, Maryland

  • McClaren Bay Heart and Vascular

    Bay City, Michigan

  • Northern Pines Health Center

    Buckley, Michigan

  • Sparrow Clinical Research Institute

    Lansing, Michigan

  • Oakland Medical Research Center

    Troy, Michigan

  • CentraCare Heart & Vascular Center

    Saint Cloud, Minnesota

  • North Mississippi Medical Center

    Tupelo, Mississippi

  • St. Louis Heart and Vascular Cardiology

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Triad Internal Medicine

    Asheboro, North Carolina

  • Cary Research Group, LLC

    Cary, North Carolina

  • Novant Health Clinical Research, LLC

    Charlotte, North Carolina

  • Novant Health Heart and Vascular Institute

    Charlotte, North Carolina

  • Lucas Research, Inc

    Morehead City, North Carolina

  • Wilmington Health Associates

    Wilmington, North Carolina

  • Metabolic and Atherosclerosis Research Center

    Cincinnati, Ohio

  • Summit Research Group, LLC

    Stow, Ohio

  • Capital Area Research

    Camp Hill, Pennsylvania

  • Monument Health Clinical Research, a department of Monument Health Rapid City Hospital, Inc

    Rapid City, South Dakota

  • Chattanooga Research & Medicine, PLLC

    Chattanooga, Tennessee

  • Cardiovascular Research of Knoxville

    Powell, Tennessee

  • PharmaTex Research, LLC

    Amarillo, Texas

  • Amarillo Heart Clinical Research Institute, Inc

    Amarillo, Texas

  • South Texas Clinical Research

    Corpus Christi, Texas

  • Diabetes and Thyroid Center of Fort Worth

    Fort Worth, Texas

  • Baylor College of Medicine

    Houston, Texas

  • Juno Research, LLC - Medical Center Office

    Houston, Texas

  • DM Clinical Research

    Houston, Texas

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.